http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
Viatris Reports Strong Fourth Quarter and Full-Year 2021 Financial Results; Issues 2022 Financial Guidance; Completes Comprehensive Strategic Review; Unveils Plan to Reshape the Company for the Future
-
Viatris to Host Virtual Investor Event and Report Fourth Quarter and Full Year 2021 Financial Results on February 28, 2022
-
Viatris' (VTRS) Generic Restasis Approved by FDA for Treatment of Dry Eye Disease
-
Viatris is First to Receive FDA Approval of Generic Restasis® (Cyclosporine Ophthalmic Emulsion 0.05%) to Treat Dry Eye Disease
-
Viatris Announces 9% Dividend Increase, Fourth Consecutive Quarterly Dividend
-
Viatris Wins Court Decisions on Sanofi Appeals of Lantus® Patent Invalidations
-
Viatris to Move its Investor Event Previously Scheduled for January 7 to no Later Than February 28 When the Company Expects to Report its Fourth Quarter 2021 Results
-
Viatris Named by Newsweek as One of America's Most Responsible Companies
-
Viatris Inc (VTRS) Wins Appeal Upholding District Court Decision Invalidating Biogen's Tecfidera Patent
-
Viatris Wins Federal Circuit Court Appeal Upholding District Court Decision Invalidating Biogen's Tecfidera® Patent
-
Viatris to Participate in Evercore ISI 4th Annual HealthCONx Conference
-
Viatris Inc (VTRS) and Biocon Launch Interchangeable SEMGLEE (insulin glargine-yfgn) Injection and Insulin Glargine (insulin glargine-yfgn) Injection
-
Viatris and Biocon Biologics Announce Launch of Interchangeable SEMGLEE® (insulin glargine-yfgn) Injection and Insulin Glargine (insulin glargine-yfgn) Injection
-
Viatris Donates $1 Million as Founding Champion to New Orleans-based SBP's "Got Your Back" fund in Support of Housing Solutions for Veterans in Disaster-Impacted Communities
-
Viatris Reports Strong Third Quarter Results, Raises 2021 Financial Guidance and Announces Virtual Investor Event on January 7, 2022
-
Viatris' First-Ever Interchangeable Insulin Biosimilar Preferred on Express Scripts' Largest Formulary
-
Viatris Inc. to Release Third Quarter 2021 Financial Results on Nov. 8, 2021
-
Viatris Named Fifth on Fortune's Change the World List
-
Viatris Inc. to Participate in Citi's 16th Annual BioPharma Conference
-
Viatris Inc. to Participate in BofA Global Healthcare Conference
-
Viatris Reports Strong Second Quarter Results
-
Viatris Inc. and Biocon Biologics Receive Historic Approval for First Interchangeable Biosimilar Semglee® (insulin glargine-yfgn injection) for the Treatment of Diabetes
-
Viatris Inc's (VTRS) Mylan Wins Dismissal of Kansas EpiPen® Case
-
Mylan Wins Dismissal of Kansas EpiPen® Direct Purchaser Case
-
Viatris Inc. to Release Second Quarter 2021 Financial Results on Aug. 9, 2021
-
Mylan Wins Significant Summary Judgment Rulings in Kansas EpiPen® Class Action
-
Viatris Inc. to Participate in Goldman Sachs 42nd Annual Global Healthcare Conference
-
Viatris Inc. Reports Strong First Quarter 2021 Financial Results, Reaffirms 2021 Guidance and Announces Inaugural Quarterly Dividend
-
Viatris Inc. Releases Inaugural Sustainability Report, Reinforcing its Commitment to Better Health and Better Communities Worldwide
-
Viatris Inc. to Participate in the 2021 RBC Capital Markets Global Healthcare Conference
-
Viatris Inc. to Participate in BofA Securities 2021 Health Care Conference
-
Viatris Inc. to Release First Quarter 2021 Financial Results on May 10, 2021
-
Viatris Inc (VTRS), Kindeva Drug Delivery Announce FDA Tentative Approval of the First Abbreviated New Drug Application Generic Version of Symbicort® (budesonide/formoterol fumarate dihydrate) Inhala
-
Viatris Inc. and Kindeva Drug Delivery Announce FDA Tentative Approval of the First Abbreviated New Drug Application Generic Version of Symbicort® (budesonide/formoterol fumarate dihydrate) Inhalatio
-
Viatris Inc. to Participate in Barclays Global Healthcare Conference
-
Viatris Inc (VTRS) Hosts Inaugural Investor Day Outlining Unique and Differentiated Business Model, High-Quality Operational Platform, and Focus on CSR and Financial Commitments
-
Viatris Inc. Hosts Inaugural Investor Day Outlining Unique and Differentiated Business Model, High-Quality Operational Platform, and Focus on CSR and Financial Commitments
-
Viatris Inc. (VRTS) Announces 2021 Financial Guidance and Reaffirms Strategic and Financial Commitments
-
Viatris Inc. Announces 2021 Financial Guidance and Reaffirms Strategic and Financial Commitments
-
Viatris Inc. to Hold Conference Call on Monday, Feb. 22, 2021, to Discuss 2021 Financial Guidance
-
Mylan (VRTS) Wins Summary Judgment in EpiPen Litigation Brought by Sanofi (SNY)
-
Mylan Wins Summary Judgment in EpiPen® Litigation Brought by Sanofi
-
Viatris Inc. Recommends Caution on TRC Capital Corp.'s Attempt to Acquire Shares at a Significant Discount via Mini-Tender Offer
-
Viatris Inc. Announces Additional Details of Previously Disclosed Global Restructuring Initiative
-
Viatris Inc. to Present at the J.P. Morgan 39th Annual Healthcare Conference January 14, 2021 and Will Host its Inaugural Investor Day March 1, 2021
-
Sesame Workshop and Viatris Inc. Launch Global Resources to Help Children and Caregivers Manage Social and Emotional Needs During Upcoming Holiday Season and Beyond
-
Viatris (VTRS) Announces FDA Tentative Approval of a Pediatric Formulation of Dolutegravir (DTG) Under PEPFAR
-
Viatris Inc. Announces FDA Tentative Approval of a Pediatric Formulation of Dolutegravir (DTG) Under PEPFAR
-
Pfizer (PFE) Completes Transaction to Combine Its Upjohn Business with Mylan (MYL)
-
Pfizer Completes Transaction to Combine Its Upjohn Business with Mylan
